

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (Retrophin)	FSGS	8-75	Sparsentan	≥ 30
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30
LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC AND ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0-75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
STUDY OF VX-147 IN ADULTS WITH APOL1-MEDIATED FSGS (Vertex)	FSGS	18-60	VX-147	N/A
STUDY OF TRPCS CHANNEL INHIBITOR IN FSGS & TREATMENT RESISTANT MINIMAL CHANGE DISEASE (NOT YET RECRUITING) (Goldfinch Bio)	FSGS, treatment-resistant MCD	18-75	GFB-887	≥ 45
ACTION (AUSTRALIA - ACTIVE, NOT RECRUITING) (Dimerix)	FSGS	18-80	Propagermanium	≥ 25
EFFICACY & SAFETY OF BLESELUMAB TO PREVENT RECURRENCE (Astellas)	De novo transplant due to FSGS	18+	Bleselumab (added to SOC)	N/A
PROTECT (Retrophin)	IgAN	18+	Sparsentan	≥ 30
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (Alnylam)	IgAN	18-65	Cemdisiran	UPCR ≥ 1 gram/24 hours
SAFETY OF OMS721 IN IGAN, MN, C3G, DENSE DEPOSIT, AND LN PATIENTS (Omeros)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	Narsoplimab	≥ 30
NEFIGARD (Calliditas)	IgAN	18+	Nefecon	≥ 45
SAFETY AND TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGAN (CALIFORNIA AND LONDON) (Aduro Biotech)	IgAN	18+	BION-1301	> 45
SAFETY AND EFFICACY OF AVB-S6-500 IN ADULTS WITH IGAN (COLORADO AND FLORIDA) (Aravive)	IgAN	18+	AVB-S6-500	≥ 45
SAFETY AND EFFICACY OF LNP023 IN ADULTS WITH KIDNEY DISEASE CAUSED BY INFLAMMATION (Novartis)	IgAN	18+	LNP023	≥ 30

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



This is a living document and was last updated on 7/16/20.

See next page for more IgAN, C3G, C3GN, and MN Trials.

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
STUDY OF VIS649 FOR IGAN (NOT YET RECRUITING) (Visterra)	IgAN	18+	VIS649	≥ 45
ACH-0144471 FOR C3G, C3GN, AND IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≥ 75
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
EFFICACY AND SAFETY OF LNP023 IN C3G PATIENTS TRANSPLANTED AND NOT TRANSPLANTED (Novartis)	C3G or C3GN	18–65	LNP023	≥ 30
EFFICACY AND SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023	≥ 45
EFFICACY AND SAFETY OF MOR202 IN ANTI-PLA2R + MEMBRANOUS NEPHROPATHY (M-PLACE) (MorphoSys)	MN	18-80	MOR202	≥ 50

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 7/16/20.



NEPHCURE[®]
Kidney International